Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Vistagen Therapeutics, Inc.VTGN · Entity 7955 | Chief Operating Officer | April 07, 2026 | April 10, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Vistagen Therapeutics, Inc.
Report date April 07, 2026 · Filed April 10, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Incentive Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.54 · Expires 2036-04-07 | Direct | 18,752 |
Reported balance
After 2026-04-07 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-04-07 · Grant · Acquired 18,752 · Balance 18,752 F1: Represents stock options (the "Options") granted pursuant to the Issuer's Amended and Restated 2019 Omnibus Equity Incentive Plan, as amended. 25% of the Options will vest on the six-month anniversary of April 7, 2026 (the "Grant Date"), and will vest in 25% installments every six months thereafter until the Options become fully vested on the two (2) year anniversary of the Grant Date. |
| Non-Qualified Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.54 · Expires 2036-04-07 | Direct | 56,248 |
Reported balance
After 2026-04-07 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-04-07 · Grant · Acquired 56,248 · Balance 56,248 F1: Represents stock options (the "Options") granted pursuant to the Issuer's Amended and Restated 2019 Omnibus Equity Incentive Plan, as amended. 25% of the Options will vest on the six-month anniversary of April 7, 2026 (the "Grant Date"), and will vest in 25% installments every six months thereafter until the Options become fully vested on the two (2) year anniversary of the Grant Date. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents stock options (the "Options") granted pursuant to the Issuer's Amended and Restated 2019 Omnibus Equity Incentive Plan, as amended. 25% of the Options will vest on the six-month anniversary of April 7, 2026 (the "Grant Date"), and will vest in 25% installments every six months thereafter until the Options become fully vested on the two (2) year anniversary of the Grant Date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| April 07, 2026 Filed Apr 10, 2026 00:40 UTC | Vistagen Therapeutics, Inc. VTGN · Entity 7955 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 56,248 | $0.00 Strike: $0.54 | $0.00 |
DisclosureSEC source: 0001998663-26-000006 · edgardoc.xml · derivative · entry 2 Prince Joshua S. · CIK 0001998663 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 56,248 Underlying: Common Stock · 56,248 shares Expires 2036-04-07 F1 · derivative.exercise_date: Represents stock options (the "Options") granted pursuant to the Issuer's Amended and Restated 2019 Omnibus Equity Incentive Plan, as amended. 25% of the Options will vest on the six-month anniversary of April 7, 2026 (the "Grant Date"), and will vest in 25% installments every six months thereafter until the Options become fully vested on the two (2) year anniversary of the Grant Date. Read SEC document |
| April 07, 2026 Filed Apr 10, 2026 00:40 UTC | Vistagen Therapeutics, Inc. VTGN · Entity 7955 | GrantIncentive Stock Option (right to buy) · Derivative | 18,752 | $0.00 Strike: $0.54 | $0.00 |
DisclosureSEC source: 0001998663-26-000006 · edgardoc.xml · derivative · entry 1 Prince Joshua S. · CIK 0001998663 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,752 Underlying: Common Stock · 18,752 shares Expires 2036-04-07 F1 · derivative.exercise_date: Represents stock options (the "Options") granted pursuant to the Issuer's Amended and Restated 2019 Omnibus Equity Incentive Plan, as amended. 25% of the Options will vest on the six-month anniversary of April 7, 2026 (the "Grant Date"), and will vest in 25% installments every six months thereafter until the Options become fully vested on the two (2) year anniversary of the Grant Date. Read SEC document |
| December 31, 2025 Filed Jan 6, 2026 01:51 UTC | Vistagen Therapeutics, Inc. VTGN · Entity 7955 | GrantCommon Stock | 4,386 | $0.56 | $2,467.56 |
DisclosureSEC source: 0001998663-26-000002 · edgardoc.xml · nonDerivative · entry 1 Prince Joshua S. · CIK 0001998663 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,249 F1 · shares: Represents acquisition of shares under the Issuer's 2019 Employee Stock Purchase Plan, as amended, in a transaction exempt under Rule 16b-3(c) and Rule 16b-3(d). Read SEC document |
| June 30, 2025 Filed Jul 1, 2025 21:51 UTC | Vistagen Therapeutics, Inc. VTGN · Entity 7955 | GrantCommon Stock | 4,882 | $1.70 | $8,299.40 |
DisclosureSEC source: 0001415889-25-018759 · form4-07012025_090735.xml · nonDerivative · entry 1 Prince Joshua S. · CIK 0001998663 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,863 F1 · kind: The Reporting Person is voluntarily reporting the acquisition of shares under the Issuer's 2019 Employee Stock Purchase Plan, as amended, in a transaction exempt under Rule 16b-3(c) and Rule 16b-3(d). Read SEC document |
| June 23, 2025 Filed Jun 25, 2025 21:15 UTC | Vistagen Therapeutics, Inc. VTGN · Entity 7955 | GrantStock Option (Right to Buy) · Derivative | 100,000 | $0.00 Strike: $1.96 | $0.00 |
DisclosureSEC source: 0001415889-25-018202 · form4-06252025_050605.xml · derivative · entry 1 Prince Joshua S. · CIK 0001998663 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2035-06-23 F1 · derivative.exercise_date: Represents stock options (the "Options") granted pursuant to the Issuer's Amended and Restated 2019 Equity Omnibus Incentive Plan, as amended. The Options will begin vesting on June 23, 2025 (the "Grant Date"), and will vest in equal monthly installments over a three-year period until the Options become fully vested on the three (3) year anniversary of the Grant Date. Read SEC document |
| December 31, 2024 Filed Jan 13, 2025 22:40 UTC | Vistagen Therapeutics, Inc. VTGN · Entity 7955 | GrantCommon Stock | 3,310 | $2.51 | $8,299.83 |
DisclosureSEC source: 0001415889-25-001402 · form4-01132025_100154.xml · nonDerivative · entry 1 Prince Joshua S. · CIK 0001998663 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,981 F1 · kind: The Reporting Person is voluntarily reporting the acquisition of shares under the Issuer's 2019 Employee Stock Purchase Plan, as amended, in a transaction exempt under Rule 16b-3(c) and Rule 16b-3(d). Read SEC document |
| June 28, 2024 Filed Jul 2, 2024 22:10 UTC | Vistagen Therapeutics, Inc. VTGN · Entity 7955 | GrantCommon Stock | 2,671 | $2.96 | $7,900.82 |
DisclosureSEC source: 0001415889-24-019028 · form4-07022024_100701.xml · nonDerivative · entry 1 Prince Joshua S. · CIK 0001998663 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,671 F1 · shares: Shares purchased under the Vistagen Therapeutics, Inc. 2019 Employee Stock Purchase Plan, as amended. Read SEC document |
| June 24, 2024 Filed Jun 27, 2024 01:29 UTC | Vistagen Therapeutics, Inc. VTGN · Entity 7955 | GrantStock Option (Right to Buy) · Derivative | 150,000 | $0.00 Strike: $3.23 | $0.00 |
DisclosureSEC source: 0001415889-24-018276 · form4-06272024_010600.xml · derivative · entry 1 Prince Joshua S. · CIK 0001998663 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 150,000 Underlying: Common Stock · 150,000 shares Expires 2034-06-24 F1 · derivative.exercise_date: Represents stock options (the "Options") granted pursuant to the Issuer's Amended and Restated 2019 Equity Omnibus Incentive Plan, as amended. The Options will begin vesting on June 24, 2024 (the "Vesting Start Date"), and will vest in equal monthly installments over a three-year period until the Options become fully vested on the three (3) year anniversary of the Vesting Start Date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.